Table 1 Growth inhibition of BCR–ABL-positive BV173 cells by combinations of imatinib with γ-irradiation, busulfan or treosulfan (MTT assay)

From: Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning